Skip to main content
OpenTrials
Completed

NCT Number: NCT05109455

Effects of a Food Supplement in the Prevention of Urinary Tract Infections in Kidney Transplant Patients.

The incidence of Urinary tract infections (UTIs) is very high in kidney transplant patients. Most UTIs occur during the first six months (82% within the first three months) of kidney transplantation and are frequently recurrent. The component D-mannose of our authorized food supplement acts by inhibiting the adherence of E.coli to the urothelium. It also has a controlled release formula that ensures the presence in urine of D-mannose and the other components during 24 hours. This is the reason why this experimental study aims to demonstrate that the oral intake of this food supplement is effective in the prevention of UTIs in kidney transplant patients.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Kidney Transplant Infection

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Hospital Universitari de Bellvitge

L'Hospitalet de Llobregat, Barcelona, Spain

About this study

The study tries to analyze the impact of a food supplement (Manosar®) on the incidence of urinary infections in patients undergoing kidney transplantation.

The patients will be randomly distributed (1: 1 ratio) into two treatment groups of 30 patients each. In one group, they will be treated with Manosar®, and in the other group they will be treated with Proanthocyanidins. All patients will be followed for 6 months, being the first three months of the study drug administration.

This experimental study is double-blinded and there are 7 monthly study visits. Properties of D-mannose and Proanthocyanidins make interesting to evaluate the clinical benefit of the use of food supplements with D-mannose and Proanthocyanidins in order to prevent the UTIs without antibiotics.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • ≥ 18 years.
  • Recipients of a cadaveric donor kidney transplant.
  • Patients who are trained to give their informed consent.

Exclusion criteria

  • Recipients of a kidney transplant who do not authorize their participation in the study by informed consent.
  • Recipients of a transplant of an organ other than the kidney.
  • Patients with Bricker or Studer neobladders.
  • Patients in need of intermittent self-catheterization prior to kidney transplantation.
  • Any medical, psychiatric or family condition that, in the opinion of the investigator, may endanger or compromise the patient's ability to participate in the study.
  • Pregnant or lactating patients.
  • Having participated in clinical trials in the previous 3 months or participating in another clinical study promoted by the pharmaceutical industry, in which the promoter already establishes the treatment for UTI.

Treatment and study plan

MANOSAR®

Dietary Supplement

MANOSAR® is an authorized food supplement that contains D-mannose, Proanthocyanidins, Ursolic Acis, vitamin complexes and ions, and protects against urinary tract infections.

Other names: Food Supplement

Proanthocyanidins

Dietary Supplement

The comparator are Proanthocyanidins of continuous-release, which are isolated from cranberry, and prevents the adhesion of uropathogenic bacteria such a E.coli to the wall of the urothelium.

Primary outcomes

  1. Change on the incidence of urinary tract infections.

    Time frame: Baseline to 1, 2, 3, 4, 5 and 6 months

    To assess the magnitude of the change from baseline incidence of urinary tract infections in kidney transplant patients at one month, two months and three months of treatment and at four, five and six months of follow-up.

Secondary outcomes

  1. Rate of three types of urinary tract infection: asymptomatic bacteriuria, cystitis, and pyelonephritis between both treatment groups.

    Time frame: Baseline to all study visits up to 6 months.

    All information regarding these infections will be recorded.

  2. Rate of urinary tract infections caused by E.coli.

    Time frame: Baseline to all study visits up to 6 months.

    E. coli will be assessed by urine cultures, which are performed according to the usual clinical practice of the site (weekly - from Visit 0 to Visit 1 (4 urine cultures); fortnightly - from Visit 1 to Visit 3 (4 urine cultures); monthly - from Visit 3 to Visit 6 (3 urine cultures)). Also if there is suspected infection based on clinical criteria there will be performed also an urine culture.

  3. Rate of patients who developed bacteremia during the episode of pyelonephritis.

    Time frame: Baseline to all study visits up to 6 months.

    This will be assessed in relation to the performance of urine cultures.

  4. Rate of safety episodes between both treatment groups.

    Time frame: From Visit 1, and at each visit, up to 6 months.

    All episodes will be recorded, whether considered minor or serious, drug-related or not.

  5. Rate of incidence of delayed renal graft function.

    Time frame: From Visit 0 to Visit 1, up to 1 month.

    This is assessed by the need for a hemodialysis session.

  6. Change from baseline in both treatment groups of concentration of glucose in renal function.

    Time frame: Baseline to all study visits up to 6 months.

    The concentration of glucose (mmol/L) is assessed by the value results of the laboratory analysis, which are completed according to the usual clinical practice of the site for the follow-up of kidney transplant patients: weekly - from Visit 0 to Visit 1 (4 tests); fortnightly - from Visit 1 to Visit 3 (4 tests); monthly - from Visit 3 to Visit 6 (3 tests).

  7. Rate of histologically confirmed acute rejection and number of patients who lost the kidney graft.

    Time frame: Baseline to all study visits up to 6 months.

    Assessed during the 6 months study.

  8. Rate of bacterial colonization of the double J catheter in both treatment groups.

    Time frame: From Visit 0 to Visit 1, up to 1 month.

    This is assessed by the microbiological analysis of the tips of the double J catheter will be performed between Visit 0 and Visit 1, once it has been removed 21-27 days after kidney transplantation.

  9. Type of bacterial colonies of the double J catheter

    Time frame: From Visit 0 to Visit 1, up to 1 month.

    This is assessed by the microbiological analysis of the tips of the double J catheter will be performed between Visit 0 and Visit 1, once it has been removed 21-27 days after kidney transplantation.

  10. Change from baseline in both treatment groups of concentration of Glomerular Filtration Rate (GFR).

    Time frame: Baseline to all study visits up to 6 months.

    The calculation of GFR (ml/min) is estimated with a blood test, which is completed according to the usual clinical practice of the site for the follow-up of kidney transplant patients: weekly - from Visit 0 to Visit 1 (4 tests); fortnightly - from Visit 1 to Visit 3 (4 tests); monthly - from Visit 3 to Visit 6 (3 tests).

  11. Change from baseline in both treatment groups of concentration of serum creatinine in renal function.

    Time frame: Baseline to all study visits up to 6 months.

    The concentration of serum creatinine (µmol/L) is assessed by the value results of the laboratory analysis, which are completed according to the usual clinical practice of the site for the follow-up of kidney transplant patients: weekly - from Visit 0 to Visit 1 (4 tests); fortnightly - from Visit 1 to Visit 3 (4 tests); monthly - from Visit 3 to Visit 6 (3 tests).

  12. Change from baseline in both treatment groups of concentration of sodium in renal function.

    Time frame: Baseline to all study visits up to 6 months.

    The concentration of sodium (mEq/L) is assessed by the value results of the laboratory analysis, which are completed according to the usual clinical practice of the site for the follow-up of kidney transplant patients: weekly - from Visit 0 to Visit 1 (4 tests); fortnightly - from Visit 1 to Visit 3 (4 tests); monthly - from Visit 3 to Visit 6 (3 tests).

  13. Change from baseline in both treatment groups of concentration of potassium in renal function.

    Time frame: Baseline to all study visits up to 6 months.

    The concentration of potassium (mEq/L) is assessed by the value results of the laboratory analysis, which are completed according to the usual clinical practice of the site for the follow-up of kidney transplant patients: weekly - from Visit 0 to Visit 1 (4 tests); fortnightly - from Visit 1 to Visit 3 (4 tests); monthly - from Visit 3 to Visit 6 (3 tests).

Sponsors and collaborators

Lead sponsor

Arafarma Group, S.A.

Industry

Registry information

Official study title

Study of a Food Supplement (Mannose and Proanthocyanidins Prolonged Release 24h) Versus Proanthocyanidins in the Prevention of Urinary Tract Infections in Kidney Transplant Patients.

Acronym: MANOTRAS

Important dates

Study start
2019
Primary completion
2021
Study completion
2023
First posted
Nov 5, 2021
Registry last updated
Mar 24, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.